Polaryx Therapeutics Inc(PLYX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PLYX Polaryx Therapeutics Inc

盘后交易 07-10 19:02:21 EDT

2.33

-0.10

-4.12%

盘后2.33

+0.00+0.05%

17:28 EDT

最高2.44	最低2.25	成交量12.99万
今开2.40	昨收2.43	日振幅7.82%
总市值1.16亿	流通市值2,978万	总股本4,985万
成交额30.17万	换手率1.02%	流通股本1,278万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PLYX","market":"US","secType":"STK","nameCN":"Polaryx Therapeutics Inc","latestPrice":2.33,"timestamp":1783713600000,"preClose":2.43,"halted":0,"volume":129903,"hourTrading":{"tag":"盘后","latestPrice":2.3312,"preClose":2.33,"latestTime":"17:28 EDT","volume":86,"amount":200.4699818,"timestamp":1783718936179,"change":0.0012,"changeRate":0.000515,"amplitude":0.000515},"delay":0,"changeRate":-0.04115226337448563,"floatShares":12782400,"shares":49846000,"eps":-0.140368,"marketStatus":"盘后交易","change":-0.1,"latestTime":"07-10 19:02:21 EDT","open":2.4,"high":2.44,"low":2.25,"amount":301669.190295,"amplitude":0.078189,"askPrice":2.4,"askSize":26,"bidPrice":2.25,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-0.140368,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1783728000000},"marketStatusCode":4,"adr":0,"listingDate":1769749200000,"exchange":"NASDAQ","adjPreClose":2.43,"preHourTrading":{"tag":"盘前","latestPrice":2.41,"preClose":2.43,"latestTime":"09:29 EDT","volume":2368,"amount":5777.6197376,"timestamp":1783690199999,"change":-0.02,"changeRate":-0.00823,"amplitude":0.028807},"postHourTrading":{"tag":"盘后","latestPrice":2.3312,"preClose":2.33,"latestTime":"17:28 EDT","volume":86,"amount":200.4699818,"timestamp":1783718936179,"change":0.0012,"changeRate":0.000515,"amplitude":0.000515},"volumeRatio":1.161732},"requestUrl":"/m/hq/s/PLYX/tweets","defaultTab":"tweets","newsList":[{"id":"1113006468","title":"H.C. Wainwright首次覆盖Polaryx Therapeutics，给予买入评级，目标价7美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1113006468","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113006468?lang=zh_cn&edition=full","pubTime":"2026-07-09 18:02","pubTimestamp":1783591336,"startTime":"0","endTime":"0","summary":"投资机构H.C. Wainwright今日宣布，对生物制药公司Polaryx Therapeutics Inc.启动首次覆盖研究。该机构给予Polaryx Therapeutics股票“买入”评级，并设定了7美元的目标价。此举意味着分析师看好该公司的发展前景与潜在价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131948077","title":"Polaryx Therapeutics完成1000万美元私募股权融资，以支持启动Soteria二期篮子试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1131948077","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131948077?lang=zh_cn&edition=full","pubTime":"2026-05-28 20:31","pubTimestamp":1779971476,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics宣布，已完成一笔1000万美元的私募股权融资。此次融资所获资金将专项用于支持其核心候选药物Soteria二期篮子试验的启动工作。\n这笔资金的注入为Polaryx推进其临床开发计划提供了关键的财务支持。二期篮子试验旨在评估Soteria在多种适应症中的疗效与安全性，标志着该药物研发进程中的一个重要里程碑。\n公司表示，此次融资的成功完成，反映了投资者对其研发管线与战略方向的信心。Polaryx计划利用这笔资金加速Soteria的临床开发，以期早日为患者带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119054078","title":"Polaryx Therapeutics四款适应症均获美国FDA快速通道资格，将纳入Soteria篮子试验评估","url":"https://stock-news.laohu8.com/highlight/detail?id=1119054078","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119054078?lang=zh_cn&edition=full","pubTime":"2026-04-21 20:32","pubTimestamp":1776774724,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics Inc宣布，其针对Soteria篮子试验计划评估的全部四种适应症，均已获得美国食品药品监督管理局授予的快速通道资格。获得FDA快速通道资格，意味着Polaryx的在研药物将有资格享受更频繁的FDA沟通、滚动审评以及优先审评等利好政策。Soteria篮子试验设计旨在高效评估单一疗法对多种相关适应症的疗效。此次四款适应症同时获批快速通道资格，进一步验证了Polaryx科研平台的技术优势及其创新疗法的应用前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194971558","title":"Polaryx Therapeutics获FDA快速通道资格，Plx-200治疗晚婴期神经元蜡样脂褐质沉积症（CLN2病）","url":"https://stock-news.laohu8.com/highlight/detail?id=1194971558","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194971558?lang=zh_cn&edition=full","pubTime":"2026-03-17 20:33","pubTimestamp":1773750788,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics公司宣布，其研发的药物Plx-200已获得美国食品药品监督管理局（FDA）授予的快速通道资格，用于治疗晚婴期神经元蜡样脂褐质沉积症（CLN2病）。这一资格将加速该药物的研发和审评进程，为患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139785167","title":"Polaryx Therapeutics获FDA安全许可函，将于2026年第三季度启动Soteria试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1139785167","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139785167?lang=zh_cn&edition=full","pubTime":"2026-03-17 20:31","pubTimestamp":1773750679,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics, Inc. 宣布，在获得美国食品药品监督管理局（FDA）的\"安全进行\"许可函后，公司计划于2026年第三季度正式启动Soteria临床试验。\n这一进展标志着Polaryx Therapeutics在药物研发道路上迈出关键一步。FDA的许可函确认了试验方案的安全性，为Soteria试验的开展扫清了监管障碍。公司预计，该试验将为其在研疗法提供重要临床数据支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156072440","title":"Polaryx Therapeutics Inc：持续积极携手合同研究机构推进2026年上半年启动临床试验计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1156072440","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156072440?lang=zh_cn&edition=full","pubTime":"2026-02-17 21:34","pubTimestamp":1771335254,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics Inc（简称PLYX）近日透露，公司正与其合同研究机构（CRO）保持紧密合作，全力推进相关临床试验的筹备工作。根据最新规划，该项试验预计将于2026年上半年正式启动。\n目前，双方团队正就试验方案设计、监管审批流程及执行细节等关键环节进行深入协调。这一进展标志着Polaryx Therapeutics Inc在创新药物研发领域迈出重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138471055","title":"Polaryx Therapeutics 宣布直接登陆纳斯达克，股票代码“PLYX”即将开始交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1138471055","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138471055?lang=zh_cn&edition=full","pubTime":"2026-02-02 21:33","pubTimestamp":1770039190,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics 已正式宣布，公司将通过直接上市方式登陆纳斯达克交易所。其普通股预计将于近期开始公开交易，股票交易代码定为“PLYX”。此次直接挂牌意味着该公司不发行新股，而是由现有股东直接将其持有的股份在公开市场进行交易。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.polaryx.com","stockEarnings":[{"period":"1week","weight":-0.1352},{"period":"1month","weight":0.0658},{"period":"3month","weight":-0.5722},{"period":"6month","weight":-0.946},{"period":"ytd","weight":-0.946}],"compareEarnings":[{"period":"1week","weight":0.0093},{"period":"1month","weight":0.0199},{"period":"3month","weight":0.1063},{"period":"6month","weight":0.083},{"period":"1year","weight":0.2045},{"period":"ytd","weight":0.1023}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Polaryx Therapeutics, Inc.最初于2014年8月22日在怀俄明州注册成立。2025年10月24日，公司完成了重新注册过程，转为内华达州公司。Polaryx是一家临床阶段的生物技术公司，致力于发现、开发和商业化针对罕见儿童溶酶体储积病（LSDs）的创新疗法。公司采用多模式治疗方法，结合小分子药物疗法和基因疗法，旨在解决这些疾病的遗传原因和下游影响。其领先的药物候选产品PLX-200，针对多种LSDs，并已进入临床试验阶段。Polaryx的药物开发战略以提供安全、有效、以患者为中心的治疗方案为核心，旨在满足这些疾病尚未解决的重大需求。","exchange":"NASDAQ","name":"Polaryx Therapeutics Inc","nameEN":"Polaryx Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Polaryx Therapeutics Inc(PLYX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Polaryx Therapeutics Inc(PLYX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Polaryx Therapeutics Inc,PLYX,Polaryx Therapeutics Inc股票,Polaryx Therapeutics Inc股票老虎,Polaryx Therapeutics Inc股票老虎国际,Polaryx Therapeutics Inc行情,Polaryx Therapeutics Inc股票行情,Polaryx Therapeutics Inc股价,Polaryx Therapeutics Inc股市,Polaryx Therapeutics Inc股票价格,Polaryx Therapeutics Inc股票交易,Polaryx Therapeutics Inc股票购买,Polaryx Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Polaryx Therapeutics Inc(PLYX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Polaryx Therapeutics Inc(PLYX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}